Webinar Briefing: Autism, Tylenol & Leucovorin — What Changed, What Didn’t
Wednesday, October 8 • 7:00 PM ET • Live Q&A
The MAHA announcements around autism, Tylenol (acetaminophen), and leucovorin have ignited intense debate—alongside real confusion for clinicians and families. We’re hosting an urgent, no-fluff briefing to clarify what was actually announced, what the evidence shows (and doesn’t), and how to communicate responsibly with patients. Recent federal communications included moves toward acetaminophen label changes in pregnancy and expanded attention to leucovorin in specific autism subgroups—sparking strong responses across the medical community. Autism Science Foundation+3U.S. Food and Drug Administration+3STAT+3
You’ll learn:
What MAHA/HHS said vs. what the data support — cleanly separated so you’re not guessing. HHS.gov+1
Acetaminophen in pregnancy: what the proposed labeling shift actually implies, current consensus vs. dissent, and how to counsel patients today. U.S. Food and Drug Administration
Where leucovorin fits (and where it doesn’t): the narrow clinical contexts (e.g., cerebral folate deficiency), evidence quality, safety notes, and documentation. The Guardian+1
Messaging that keeps you compliant: what to say, what to avoid, and how to update consent forms, website copy, and staff talking points (immediately).
Live Q&A: bring real cases and patient-communication challenges.
Who Should Attend?
Prescribers, practice owners, clinical leads, patient-facing staff, and parent advocates who need clarity—fast.
Speakers:
Moderator: Dianne Morrell — Regulatory & Compliance Lead, APN
Faculty: Luis Martinez, MD, MPH — Regenerative & Integrative Medicine
Faculty: Amy Wrenn, ARNP — Women’s Health, BHRT, Weight Mgmt & Peptides
Logistics:
When: Wednesday, October 8, 7:00 PM ET (60–75 minutes)
Where: Live Google Meet (recording sent to registrants)
Cost: Free, but seats are limited (and yes, we mean it)
Our Promise (and your edge): We’ll cut through hype and politics, translate the data, and hand you ready-to-use language for patients and staff. Zero theatrics, maximum signal.
Compliance Note: This webinar is educational only. We do not make safety/efficacy claims for compounded or off-label therapies. Treatment decisions must be individualized and made in consultation with qualified healthcare professionals. KFF Health News